Image
user avatar
Shankar Siva
@_ShankarSiva
Radiation Oncologist at the Peter MacCallum Cancer Centre @petermaccc, Professor of Medicine, University of Melbourne, Australia 🇦🇺. Views are my own. #radonc
Melbourne, Victoria
petermac.org/expert-finder/…
Joined July 2012
865
Following
9,291
Followers
  • Pinned
    user avatar
    Shankar Siva
    @_ShankarSiva
    Mar 12, 2024
    1/ Thank you 🙏🏾, patients, families, and investigators, for contributing to the SEISMIC 🫁trial out now @LancetRespirMed - shorturl.at/qxMUY. Led by 🫁@DanSteinfort, this international multicentre recruited n=155 trial from 🇦🇺, 🇨🇦, 🇺🇸, 🇳🇱 #radonc @tssmn @PeterMacRadOnc
    Image
    66K
  • user avatar
    Shankar Siva
    @_ShankarSiva
    Oct 23, 2022
    @ErinGillespieMD presents a provocative phase II RCT of prophylactic #radiotherapy to asymptomatic but high risk bone Mets. N=93 Convincing home run, 29% vs 1.6% skeletal related events, with an ⬆️ OS benefit! Remained significant on MVA #ASTRO22 #OncoAlert
    Image
    Image
    Image
    Image
  • user avatar
    Shankar Siva
    @_ShankarSiva
    Oct 1, 2023
    🧵1/ 🙏🏾🙏🏾Thank you patients, families, trial staff and investigators for participating in @TROGfightcancer 15.03 FASTRACK II! This trial recruited n=70 across 8 sites in 🇦🇺 and 🇳🇱 #ASTRO23! #radonc #kcsm #radiotherapy @ANZUPtrials @KidneyCancer
    Image
    83K
  • user avatar
    Shankar Siva
    @_ShankarSiva
    Nov 16, 2022
    🧵1/ Wide adoption of SABR for primary #kidneycancer is limited by long-term data. Online today @TheLancetOncol; 5-yr outcomes in 190 patients. 5% local failure rates, 95% cancer-specific survival. Thanks @ElsevierConnect for 50-day link: #radonc #kcsm sciencedirect.com/science/articl…
  • user avatar
    Shankar Siva
    @_ShankarSiva
    Aug 29, 2021
    1/ 🙏 patients, investigators and funders for @TROGfightcancer 13.01 SAFRON II trial at #ESTRO21. n=90 pts with 133 pulmonary oligometastases, across 13 centers in 🇳🇿+🇦🇺. Median F/U = 3 years, randomization for single (SF) 28Gy vs 48Gy in 4fx (MF). #radonc #LCSM @PeterMacCC
    Image
  • user avatar
    Shankar Siva
    @_ShankarSiva
    Sep 18, 2023
    🍾😋🤗 yay! Thank you for all the support from mentors, mentees and collaborators along the way 🙌🏽 ….As they say it takes a village to raise a child….. #radonc @PeterMacRadOnc
    user avatar
    Peter Mac Research
    @PeterMacRes
    Sep 18, 2023
    Congratulations to @_ShankarSiva on his appointment to Honorary Clinical Professor with the Sir Peter MacCallum Department of Oncology, at the University of Melbourne. Prof Siva leads the Stereotactic Ablative Body Radiotherapy (SABR) program @PeterMacCC. #radiotherapy #cancer
    Image
    24K
  • user avatar
    Shankar Siva
    @_ShankarSiva
    Oct 25, 2022
    Late breaking abstracts #ASTRO22 - @ChadTangMD EXTEND trial; oligometastatic #prostatecancer. Intermittent ADT + SABR versus ADR alone extends PFS, but importantly time men enjoy off ADT in the long term (eugonadal PFS). Important patient centric endpoint! 👏🏽⭐️ @OncoAlert #pcsm
    Image
    Image
    Image
    Image
  • user avatar
    Shankar Siva
    @_ShankarSiva
    Feb 17, 2023
    Joe O’Sullivan presents CHHiP trial update 10-year data confirms 60/20 hypofractionated #radiotherapy as the standard of care for #prostatecancer (mostly intermediate). Good to see late significant GI/GU toxicity <1-2% at 10 years! @ASCO #GU23 #radonc #pcsm @OncoAlert
    Image
    Image
    Image
    30K
  • user avatar
    Shankar Siva
    @_ShankarSiva
    Feb 6, 2025
    📢🚨 Hot off the press @TheLancetOncol for #kidneycancer! shorturl.at/kAGVd. SABR vs thermal ablation; - Despite ⏫age, ⏬worse GFR, and ⏫tumours for SABR - SABR ⬆️effective than TA (at 1, 2 and 5 yrs) - esp for RCC >4cm - same renal decline (p=0.75) - similar F/U #radonc
    Image
    Image
    Image
    Image
    33K
  • user avatar
    Shankar Siva
    @_ShankarSiva
    Apr 11, 2024
    What I learned in 🇨🇱 today … $5mill = one #radiotherapy machine☢️, can treat 10k patients. $5mill = 135 patients worth of trastuzumab. 🧐 @TheLancetOncol - tinyurl.com/6bry9a2a “an essential pillar in multi-D oncology…an inexpensive modality” - 👏🏽 well said @TargetingCancer
    Image
    35K
  • user avatar
    Shankar Siva
    @_ShankarSiva
    Jun 11, 2021
    💪🦾@CDNCancerTrials @SahgalArjun in collab. with @TROGfightcancer - SC.24 phase III here - bit.ly/3wl2DAr. n=229 from 🇨🇦 +🇦🇺, SBRT (24Gy/2) vs standard #radiotherapy (20Gy/5) for painful spinal mets. 3-month pain CR ⬆️36% vs ⬇️14%, p<0.01. Is SBRT the new SoC? #radonc
    Image
    Image
    Image
    Image
  • user avatar
    Shankar Siva
    @_ShankarSiva
    Sep 29, 2025
    💥Phase III BART trial (n=153) in locally advanced #BladderCancer after cystectomy + chemo: 🔹 RT (n=77) vs Obs (n=76) 🔹2-yr locoregional recurrence: 8% RT vs 26% Obs (p=0.006) 🔹OS trend ↑RT (68% vs 57%), not sig 🔹No ↑ severe late adverse events 👉Adjuvant RT ↑ control &
    Image
    Image
    Image
    Image
    33K
  • user avatar
    Shankar Siva
    @_ShankarSiva
    Apr 11, 2019
    It's here! SABR-COMET published in @TheLancet - bit.ly/2Gh2Qx4 - randomised trial of ablation in oligometastastic (1-5) #cancer. Double median PFS (6 mo vs 12 mo) and increased med overall survival (28 mo vs 41mo, p=0.09). @drdavidpalma et al. #lcsm #pcsm #radonc #tssmn
    Image
    Image
    Image
    Image
  • user avatar
    Shankar Siva
    @_ShankarSiva
    Aug 25, 2022
    STOMP and ORIOLE long term outcomes. Metastasis-directed SABR in oligometastatic #prostatecancer ⬆️PFS from 5.9mo to 11.9mo (HR 0.44, p<0.001). Men without Hi-risk mutations on nGEN seq. had rPFS of 22.6mo. Article here ➡️ bit.ly/3pHD7Ub @JCO_ASCO #radonc #pcsm @gu_onc
    Image
    Image
    Image
    Image